ABSTRACT
PURPOSE: HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuzumab and chemotherapy (CT) in early-stage HER2-positive BC. METHODS: A retrospective, multicentre study was conducted on patients diagnosed with HER2-positive early BC treated with neoadjuvant pertuzumab and trastuzumab plus CT at 13 Spanish sites. The primary endpoint was pathological complete response (pCR). RESULTS: A total of 310 patients were included. Pertuzumab and trastuzumab were combined with anthracyclines and taxanes, carboplatin and docetaxel, and taxane-based CT in 77.1%, 16.5%, and 6.5% of patients, respectively. Overall, the pCR rate was 62.2%. The pCR was higher amongst patients with hormone receptor-negative tumours and with tumours expressing higher levels of Ki-67 (> 20%). After postoperative adjuvant treatment, 13.9% of patients relapsed. Those patients who did not achieve pCR, with tumours at advanced stages (III), and with node-positive disease were more likely to experience distant relapse. Median overall survival (OS) and distant disease-free survival (D-DFS) were not reached at the study end. The estimated mean OS and D-DFS times were 7.5 (95% CI 7.3-7.7) and 7.3 (95% CI 7.1-7.5) years, respectively (both were significantly longer amongst patients who achieved pCR). Grade 3-4 anti-HER2 related toxicities were reported in six (1.9%) patients. CONCLUSION: Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.
ABSTRACT
Introducción La pandemia por COVID-19 ha modificado nuestra actividad asistencial habitual en los últimos meses. Debido al colapso hospitalario se han suspendido consultas, pruebas diagnósticas e intervenciones quirúrgicas, con el objetivo también de reducir la exposición de pacientes al SARS-CoV-2 en el medio hospitalario. Sin embargo, esto ha provocado un retraso en la atención de otros problemas sanitarios. Material y métodos Analizamos y comparamos los datos de la Unidad de Mama en un hospital de segundo nivel, en cuanto a la actividad del Programa de Diagnóstico Precoz de Cáncer de Mama (PDPCM), los diagnósticos de cáncer realizados, así como las pacientes intervenidas durante los meses de marzo a mayo de 2020, con respecto al mismo período del año anterior. Resultados El número de pacientes atendidas en el PDPCM en los meses de marzo a mayo de 2020 se ha reducido en un 91,7%, y las pacientes atendidas en el Servicio de Radiodiagnóstico del hospital en un 54,2%. La actividad quirúrgica también se ha visto mermada en un 57,69% con respecto al mismo periodo del año anterior. Conclusiones La disminución de la actividad del PDPCM y Radiología conllevan a un retraso diagnóstico que concluirá con un aumento de lista de espera y demora en el tratamiento, lo que posiblemente derive en un diagnóstico en estadios más avanzados de la enfermedad. (AU)
Introduction The COVID-19 pandemic has changed routine clinical activity in the last few months. Because our hospital was overwhelmed and to prevent patient exposure to SARS-CoV-2 in the hospital setting, consultations, diagnostic tests, and surgical interventions have been postponed. However, this has provoked a delay in the care of other health problems. Material and methods We analysed and compared the data from the breast unit of a second-level hospital in terms of the activity of the Early Breast Cancer Detection Programme (EBCDP), the cancer diagnoses made, and the patients undergoing surgery from March to May, 2020, compared with the same period in the previous year. Results The number of patients attended in the EBCDP in March and May decreased by 91.7% and those attended in the Radiodiagnostics Service of the hospital fell by 54.2%. Surgical activity also decreased by 57.69% compared with the same period in 2019. Conclusions The decrease in the activity of the EBCDP and Radiology Service have led to a diagnostic delay which will, in turn, increase waiting lists and delay treatment. These factors will possibly lead to tumours being diagnosed in more advanced stages. (AU)
Subject(s)
Breast Neoplasms/surgery , Breast Neoplasms/diagnosis , Early Detection of Cancer , RadiologyABSTRACT
OBJETIVO: Revisión bibliográfica del diagnóstico, tratamiento y supervivencia del carcinoma de mama metastásico que cursa con carcinomatosis peritoneal. PACIENTES Y MÉTODOS: Presentamos el caso de una paciente en tratamiento en nuestro hospital comentándose los aspectos clínicos, diagnósticos y terapéuticos de interés. CONCLUSIÓN: Las metástasis del tracto gastrointestinal extra-hepáticas secundarias a tumor de mama son poco comunes (8-10%). La carcinomatosis peritoneal presenta una baja incidencia, habiéndose descrito pocos casos en la literatura, siendo la mayoría de tipo lobulillar infiltrante. Nuestro caso tratado de carcinomatosis peritoneal de origen mamario ductal infiltrante lo hace aún más infrecuente
AIM: We provide a literature review of the diagnosis, treatment and survival of metastatic breast cancer with peritoneal carcinomatosis. PATIENTS AND METHODS: We present a case treated in our institution and discuss relevant clinical, diagnostic, and therapeutic features. CONCLUSION: Extra-hepatic gastrointestinal metastasis from breast cancer is infrequent (8%-10%). The incidence of peritoneal carcinomatosis is low, with few cases reported in the literature, mostly from invasive lobular carcinoma. Our case of invasive ductal carcinoma is even less frequent
Subject(s)
Humans , Female , Middle Aged , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Peritoneal Neoplasms/secondary , Sigmoid Neoplasms/pathology , Neoplasms, Multiple Primary/pathology , Adenocarcinoma/pathology , Peritoneal Neoplasms/pathology , Sigmoid Neoplasms/secondaryABSTRACT
INTRODUCCIÓN: La pandemia por COVID-19 ha modificado nuestra actividad asistencial habitual en los últimos meses. Debido al colapso hospitalario se han suspendido consultas, pruebas diagnósticas e intervenciones quirúrgicas, con el objetivo también de reducir la exposición de pacientes al SARS-CoV-2 en el medio hospitalario. Sin embargo, esto ha provocado un retraso en la atención de otros problemas sanitarios. MATERIAL Y MÉTODOS: Analizamos y comparamos los datos de la Unidad de Mama en un hospital de segundo nivel, en cuanto a la actividad del Programa de Diagnóstico Precoz de Cáncer de Mama (PDPCM), los diagnósticos de cáncer realizados, así como las pacientes intervenidas durante los meses de marzo a mayo de 2020, con respecto al mismo período del año anterior. RESULTADOS: El número de pacientes atendidas en el PDPCM en los meses de marzo a mayo de 2020 se ha reducido en un 91,7%, y las pacientes atendidas en el Servicio de Radiodiagnóstico del hospital en un 54,2%. La actividad quirúrgica también se ha visto mermada en un 57,69% con respecto al mismo periodo del año anterior. CONCLUSIONES: La disminución de la actividad del PDPCM y Radiología conllevan a un retraso diagnóstico que concluirá con un aumento de lista de espera y demora en el tratamiento, lo que posiblemente derive en un diagnóstico en estadios más avanzados de la enfermedad
INTRODUCTION: The COVID-19 pandemic has changed routine clinical activity in the last few months. Because our hospital was overwhelmed and to prevent patient exposure to SARS-CoV-2 in the hospital setting, consultations, diagnostic tests, and surgical interventions have been postponed. However, this has provoked a delay in the care of other health problems. MATERIAL AND METHODS: We analysed and compared the data from the breast unit of a second-level hospital in terms of the activity of the Early Breast Cancer Detection Programme (EBCDP), the cancer diagnoses made, and the patients undergoing surgery from March to May, 2020, compared with the same period in the previous year. RESULTS: The number of patients attended in the EBCDP in March and May decreased by 91.7% and those attended in the Radiodiagnostics Service of the hospital fell by 54.2%. Surgical activity also decreased by 57.69% compared with the same period in 2019. CONCLUSIONS: The decrease in the activity of the EBCDP and Radiology Service have led to a diagnostic delay which will, in turn, increase waiting lists and delay treatment. These factors will possibly lead to tumours being diagnosed in more advanced stages
